An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
VERDICT
The label
Markup
read at $143.62
Guardant Health Inc holds its Markup at $143.62.
PHPhase · the trend structure carries the Markup label
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-29
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 10 days
Price
$143.62
Valuation
N/A trailing · -331.53 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.59
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$143.62
N/A P/E · -331.53 fwd
Our fair value
$185.00
29% discount
Analyst target (avg)
$185.00
+29% to current
Target low $90.00Analyst target rangeTarget high $215.00
▲ current $143.62 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$143.62
you are here
Conservative
$90.00
-37%
Analyst avg
$185.00
+29%
Our fair value
$185.00
+29%
Analyst high
$215.00
+50%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
48.30%
Profit margin
-40.10%
Analyst consensus
Strong Buy · 24 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Liquid biopsies still deep in the red
A simple blood draw can spot cancer mutations without a tissue sample, and Guardant Health sells exactly that service to hospitals and drug makers. Revenue is rising 48% a year as adoption grows, yet the business still posts a 40% negative profit margin and a forward P/E of minus 360 times.
We pass. The company earns a narrow moat and clears the ethical screen, while analysts see upside to 185 dollars from the current 155.87 price. None of that is enough to generate an opportunity rating once the heavy losses and limited competitive edge are weighed.
The real risk is simple arithmetic: rapid sales growth has not yet produced profits, and any slowdown in test volumes would leave the valuation looking even more stretched. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 159%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (23 analysts) rates it strong buy, with a mean price target of $142. Entered 2026-07-18 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markup$131.62+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 159%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (23 analysts) rates it strong buy, with a mean price target of $142.
2026-07-03Markup$131.62+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$131.62Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
